Trial Profile
A feasibility study to assess the effects of AntiretroViral Intensification with Cenicriviroc for the management of HIV-associated Cognitive Impairment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Cenicriviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms The AVICCI study
- 29 Jun 2019 Status changed to discontinued.
- 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection
- 01 Oct 2016 Status changed from active, no longer recruiting to completed.